Clinical Trials · NCT07010432
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 144
- Start date
- Jun 2025
- Locations
- 1 site, Denmark
- Primary endpoint
- Relative change in volumetric bone mineral density (vBMD) of the total hip assessed by quantitative computed tomography (QCT)